

A trial of medications in comparison to dummy tablets for the treatment of drooling caused by clozapine.

Submission date 05/12/2023	Recruitment status Recruiting	☒ Prospectively registered
		☐ Protocol
Registration date 26/01/2024	Overall study status Ongoing	☐ Statistical analysis plan
		☐ Results
Last Edited 28/05/2026	Condition category Mental and Behavioural Disorders	☐ Individual participant data
		☒ Record updated in last year

Plain English summary of protocol

Background and study aims

Clozapine is an antipsychotic medication used to help treat the symptoms of schizophrenia and is also sometimes used to treat other mental health conditions. It is the most effective antipsychotic medication for many people and it is important to keep taking it. Clozapine can cause different side effects and people tell us one of the most upsetting is excessive drooling. Doctors call this 'clozapine-induced hypersalivation' (CIH or drooling). People with CIH/drooling tell us they often have to wipe the saliva from their mouth during the day and their pillow becomes very wet at night which can sometimes make the skin on their face sore. CIH can be very embarrassing and lead to some patients wanting to stop clozapine treatment. For most patients this is not a good idea as their mental illness is likely to come back and they may need to be admitted to hospital. Currently, there is no proven treatment for CIH. The medication usually prescribed is called hyoscine but we don't know if hyoscine helps although doctors think it might. Hyoscine can cause unpleasant side effects such as bowel problems (constipation) and thinking problems (making attention and concentration worse). Some studies suggest a different medication called glycopyrrolate might be helpful for CIH and may cause fewer thinking problems. But it may still cause other side effects like constipation. Patients have told us that it is important for them to know which medications may improve CIH and what the side effects are so they can make an informed choice about whether or not to take any of these medicines based on their mental illness symptoms and experience of side effects. Our study will find out if either hyoscine or glycopyrrolate can improve CIH/drooling by comparing patients taking these medications with patients taking a dummy treatment (placebo). If both help reduce CIH/drooling we will compare the two medications to see which one causes fewer side effects and ask which one patients prefer.

Who can participate?

Patients aged 18 - 65 years, with clozapine-induced hypersalivation.

What does the study involve?

Participants will be randomly assigned to receive either hyoscine hydrobromide, glycopyrronium bromide (glycopyrrolate), or a placebo over a period of 12 weeks.

What are the possible benefits and risks of participating?

Benefits:

Not provided at time of registration

Risks:

Burden of visits and assessments: Treatment visits have been aligned with routine care clozapine clinic visits (every 4 weeks). Visits at home instead of the clozapine clinic can be arranged if participants prefer. Service users have been involved in GOTHIC2 throughout its development. The participant pathway and all patient-facing documentation have been developed with full PPIE involvement and use of the FAST-R service.

Treatment Intervention: A summary of the more important risks are as follows:

Hyoscine hydrobromide (Kwells): Very common side effects (more than one in 10) include feeling a bit sleepy or dizzy, eyesight being a bit blurry and having a dry mouth. Constipation is also possible. All of these side effects can also happen with clozapine (nIMP) so participants may not notice any difference. There is a very small chance participants might find it more difficult to concentrate or think clearly. The comprehensive list of undesirable effects is listed in the relevant SmPC.

Side effects from a placebo are unlikely as it is a dummy capsule with inactive ingredients. The main ingredient, Magnesium stearate, is generally safe to consume but too much of it can have a laxative effect.

Glycopyrronium bromide (Glycopyrrolate): Very common side effects (more than 1 in 10) include dry mouth, constipation, diarrhoea, vomiting, flushed skin, nasal congestion, having difficulty emptying the bladder (urinary retention), feeling irritable and experiencing a reduction in chest secretions. Common side effects (experienced by one in 10 to 1 in 100 people) include chest infections (including pneumonia), urine infections, feeling agitated or drowsy, nose bleeds, rash and fever. The comprehensive list of undesirable effects is listed in the relevant SmPC.

Placebo side effects are unlikely as it is a dummy capsule with inactive ingredients. The main ingredient, Magnesium stearate, is generally safe to consume but too much of it can have a laxative effect. This is also a component of clozapine (nIMP).

Treatment modifications: trial participants should not be prescribed any other CIH treatment. Participants are prescribed two capsules per day in week one and three capsules per day from week two until the end of treatment at week twelve. Should the treating clinician have any concerns about tolerance then the dose may be reduced in week one to one capsule per day and the dose can be reduced in weeks 2-12 to one or two capsules per day. The reduction and reason for the reduction should be recorded in the appropriate eCRF.

Dose modifications: Participants who discontinue clozapine treatment should also discontinue trial treatment. The discontinuation of trial treatment and reason must be recorded in the appropriate eCRF.

Where is the study run from?

University of Liverpool (UK)

When is the study starting and how long is it expected to run for?

November 2023 to August 2027

Who is funding the study?

National Institute for Health and Care Research (NIHR) (UK).

Who is the main contact?

Ms Julie Perry, gothic2@liverpool.ac.uk

Dr Inti Qurashi, Inti.Qurashi@merseycare.nhs.uk

Contact information

Type(s)

Public, Scientific

Contact name

Dr Julie Perry

Contact details

Liverpool Clinical Trials Centre , Block C, Waterhouse Building, 1-3 Brownlow Street
Liverpool
United Kingdom
L69 3GL
+44 151 795 8577
gothic2@liverpool.ac.uk

Type(s)

Principal investigator

Contact name

Dr Inti Qurashi

Contact details

Parkbourn
Liverpool
United Kingdom
L31 1HW
+44 151 472 4045
Inti.Qurashi@merseycare.nhs.uk

Additional identifiers

Integrated Research Application System (IRAS)

1008055

Central Portfolio Management System (CPMS)

58120

Protocol serial number

UoL001694

Study information

Scientific Title

A 3-arm multi-centre randomised placebo-controlled trial of glycopyrrolate or hyoscine hydrobromide for the treatment of clozapine-induced hypersalivation

Acronym

GOTHIC2

Study objectives

Primary objective:

To ascertain the efficacy of either hyoscine hydrobromide or glycopyrrolate in comparison to placebo in the treatment of CIH.

Secondary objectives:

1. To establish which of glycopyrrolate or hyoscine hydrobromide, if any, is associated with fewer cognitive side-effects using a validated assessment measure.
2. To establish which of glycopyrrolate or hyoscine hydrobromide, if any, is associated with fewer ADRs.

Added 01/05/2024:

Exploratory objective:

1. To establish whether clozapine plasma levels are associated with clozapine ADRs (moved from secondary objectives)

Updated 27/05/2026: The open-label phase was removed:

Open-label objectives:

1. To increase knowledge of the safety profile of the active IMPs in the treatment of CIH.
2. To establish the effectiveness of active IMPs over the open-label phase.

Ethics approval required

Ethics approval required

Ethics approval(s)

Approved 24/01/2024, London - Fulham Research Ethics Committee (2 Redman Place, Stratford, London, E20 1JQ, United Kingdom; +44 (0)207 104 8084, (0)207 104 8286; fulham.rec@hra.nhs.uk), ref: 23/LO/1002

Primary study design

Interventional

Study design

Interventional double-blind randomized controlled trial

Study type(s)

Efficacy, Safety

Health condition(s) or problem(s) studied

Clozapine induced hypersalivation (CIH)

Interventions

Participants will be randomised via a secure (24-hour) web-based randomisation system controlled centrally by the LCTC to receive either hyoscine hydrobromide, glycopyrronium bromide (glycopyrrolate) or placebo in a ratio of 1:1:1.

Route of administration: capsules for oral administration

IMP1: Hyoscine hydrobromide (over-encapsulated)

Dose: Week 1: 300 micrograms (1 capsule) twice daily

Weeks 2-12: 300 micrograms (1 capsule) three times daily

IMP2: Glycopyrronium bromide (glycopyrrolate) (over-encapsulated)

Dose: Week 1: 1 mg (1 capsule) twice daily

Weeks 2-12: 1 mg (1 capsule) three times daily

Placebo: capsules filled with a lactose & magnesium stearate blend

Dose: Week 1: 1 capsule twice daily

Weeks 2-12: 1 capsule three times daily

Trial treatment duration is 12 weeks with an optional 12-week open-label follow-up period.

Updated 28/05/2026:

Trial treatment duration is 12 weeks.

Intervention Type

Drug

Phase

Phase III

Drug/device/biological/vaccine name(s)

Hyoscine Hydrobromide [Hyoscine Hydrobromide 300 microgram] , Glycopyrronium Bromide [Glycopyrronium Bromide]

Primary outcome(s)

Current primary outcome as of 27/05/2026:

Hypersalivation measured using the Drooling Rating Scale at Baseline, T 1, 2, 4, 6, 8, 12

Previous primary outcome:

Hypersalivation measured using the Drooling Rating Scale at Baseline, T 1, 2, 4, 6, 8, 12 and Optional T16, 20, 24

Key secondary outcome(s)

1. Neuroleptic side-effects measured using the Liverpool University Neuroleptic Side Effect Rating Scale (LUNSERS) PROM (participant reported outcome measure) at Baseline, T 4, 8, 12 and Optional T16, 20, 24
2. Anticholinergic side effects measured using the Liverpool Anticholinergic Side-effects Scale (LASS) PROM at Baseline, T 4, 8, 12 and Optional T16, 20, 24
3. Sustained attention and Verbal Recognition Memory (VRM) measured using the Cambridge Neuropsychological Test Automated Battery (CANTAB) via a pre-loaded tablet device at Baseline and T12
4. Nocturnal hypersalivation measured using the Nocturnal Hypersalivation Rating Scale (NHRS) PROM at Baseline, T 1, 2, 4, 6, 8, 12 and Optional T16, 20, 24
5. Self-esteem measured using the Rosenberg Self-esteem scale (RSE) PROM at Baseline and T12
6. Hospital admission (whether for physical or psychiatric reasons) from Consent up to T12 and Optional follow-up to T24
7. Constipation measured using the Patient assessment of constipation and symptoms (PAC-SYM) at Baseline, T4, 8, 12 and Optional T24
8. Social functioning measured using the Personal and Social Performance scale (PSP) conducted via interview at Baseline and T12
9. Symptoms of schizophrenia measured using the Positive and negative syndrome scale (PANSS) conducted via interview at Baseline and T12

10. Effect and tolerability of treatment measured by premature discontinuation of study treatment/Continuation at T12
11. Discontinuation of clozapine
12. Serious Adverse Events reported from Consent up to T12 and Optional follow-up to T24

Updated 01/05/2024:

Exploratory outcome measure:

1. Clozapine plasma levels from blood analysis at Baseline and T12 (moved from secondary outcome measures)

Completion date

01/08/2027

Eligibility

Key inclusion criteria

1. Aged 18 to 65 years inclusive.
2. English speaking.
3. Prescribed clozapine for a minimum of three months.
4. Experiencing hypersalivation with a minimum score of 4 on the Drooling Rating Scale (DRS) and are either:
 - 4.1. Currently not receiving treatment for CIH, OR
 - 4.2. Receiving drug treatment for CIH and agreeable to a 48-hour washout period
5. Written and informed consent obtained from participant (with capacity and ability) and agreement of participant to comply with the requirements of the trial prior to study specific procedures.

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Mixed

Lower age limit

18 Years

Upper age limit

65 Years

Sex

All

Total final enrolment

0

Key exclusion criteria

Current participant exclusion criteria as of 27/05/2026:

1. Medical conditions that could influence hypersalivation (e.g., Parkinson's Disease).
2. Neurological conditions that could affect cognitive functioning during the course of the study (e.g., unstable epilepsy).
3. History of an allergic reaction to hyoscine hydrobromide
4. History of an allergic reaction to glycopyrrolate.
5. Any of the following contra-indications to hyoscine hydrobromide or glycopyrrolate as stated in the British National Formulary:
 - 5.1. Prostatic enlargement
 - 5.2. Myasthenia gravis
 - 5.3. Pyloric stenosis
 - 5.4. Paralytic ileus
 - 5.5. Glaucoma
 - 5.6. Hepatic Impairment
6. Any of the following cautions to hyoscine hydrobromide or glycopyrrolate as stated in the British National Formulary:
 - 6.1. Chronic heart failure
 - 6.2. Stomach ulcer
 - 6.3. Ulcerative colitis
 - 6.4. Significant liver disease that in the opinion of the CI or PI is a contraindication
 - 6.5. Down's syndrome
 - 6.6. Arrhythmia and/or history of myocardial infarction
 - 6.7. Overactive thyroid gland.
 - 6.8. Unstable angina
7. Current prescription for potassium chloride, digoxin, amantadine, levodopa, tricyclic antidepressants or monoamine oxidase inhibitors
8. Pregnant, trying to conceive or breastfeeding.
9. Participation in another drug study within the preceding 12 weeks (or within 5 half-lives of an IMP, whichever is longer) or use of other investigational drugs.
10. Active suicidal ideation as assessed within usual care.
11. Known sensitivity to any interventions or excipients.
12. Known history of intestinal obstruction.
13. Known history of urinary retention.
14. Severe renal impairment (eGFR <30 ml/min/1.73m²).
15. Known history of brain tumour or encephalitis.
16. Any contraindication to dispensing monthly supply of medications.
17. Unable to swallow tablets.

Previous participant exclusion criteria as of 07/03/2024:

1. Medical conditions that could influence hypersalivation (e.g., Parkinson's Disease).
2. Neurological conditions that could affect cognitive functioning during the course of the study (e.g., unstable epilepsy).
3. History of an allergic reaction to hyoscine hydrobromide
4. History of an allergic reaction to glycopyrrolate.
5. Any of the following contra-indications to hyoscine hydrobromide or glycopyrrolate as stated in the British National Formulary:
 - 5.1. Prostatic enlargement
 - 5.2. Myasthenia gravis
 - 5.3. Pyloric stenosis
 - 5.4. Paralytic ileus
 - 5.5. Glaucoma
 - 5.6. Hepatic Impairment

6. Any of the following cautions to hyoscine hydrobromide or glycopyrrolate as stated in the British National Formulary:
- 6.1. Chronic heart failure
 - 6.2. Stomach ulcer
 - 6.3. Ulcerative colitis
 - 6.4. Significant liver disease that in the opinion of the CI or PI is a contraindication
 - 6.5. Down's syndrome
 - 6.6. Arrhythmia and/or history of myocardial infarction
 - 6.7. Overactive thyroid gland.
 - 6.8. Unstable angina
7. Current prescription for potassium chloride, digoxin, amantadine, levodopa, tricyclic antidepressants or monoamine oxidase inhibitors
8. Pregnant, trying to conceive or breastfeeding.
9. Sexually active heterosexual patients who are unable or unwilling to use contraception during the study (see section 10.4).
10. Participation in another drug study within the preceding 12 weeks (or within 5 half-lives of an IMP, whichever is longer) or use of other investigational drugs.
11. Active suicidal ideation as assessed within usual care.
12. Known sensitivity to any interventions or excipients.
13. Known history of intestinal obstruction.
14. Known history of urinary retention.
15. Severe renal impairment (eGFR <30 ml/min/1.73m²).
16. Known history of brain tumour or encephalitis.

Previous participant exclusion criteria:

1. Medical conditions that could influence hypersalivation (e.g., Parkinson's Disease).
2. Neurological conditions that could affect cognitive functioning during the course of the study (e.g., unstable epilepsy).
3. History of an allergic reaction to hyoscine hydrobromide
4. History of an allergic reaction to glycopyrrolate.
5. Any of the following contra-indications to hyoscine hydrobromide or glycopyrrolate as stated in the British National Formulary:
 - 5.1. Prostatic enlargement
 - 5.2. Myasthenia gravis
 - 5.3. Pyloric stenosis
 - 5.4. Paralytic ileus
 - 5.5. Glaucoma
 - 5.6. Hepatic Impairment
6. Any of the following cautions to hyoscine hydrobromide or glycopyrrolate as stated in the British National Formulary:
 - 6.1. Chronic heart failure
 - 6.2. Stomach ulcer
 - 6.3. Ulcerative colitis
 - 6.4. Significant liver disease that in the opinion of the CI or PI is a contraindication
 - 6.5. Down's syndrome
 - 6.6. Arrhythmia and/or history of myocardial infarction
 - 6.7. Overactive thyroid gland.
 - 6.8. Unstable angina
7. Current prescription for a) potassium chloride, b) digoxin, c) amantadine, or d) levodopa.
8. Pregnant, trying to conceive or breastfeeding.
9. Patients who are unable or unwilling to use contraception during the study or abstain from sexual intercourse (see section 10.4).

10. Participation in another drug study within the preceding 12 weeks or use of other investigational drugs.
11. Active suicidal ideation as assessed within usual care.
12. Known sensitivity to any interventions or excipients.
13. Known history of intestinal obstruction.
14. Known history of urinary retention.
15. Severe renal impairment (eGFR <30 ml/min/1.73m²).
16. Known history of brain tumour or encephalitis.

Date of first enrolment

20/08/2024

Date of final enrolment

01/11/2026

Locations

Countries of recruitment

United Kingdom

England

Wales

Study participating centre

Mersey Care NHS Foundation Trust

V7 Building

Kings Business Park

Kings Drive

Prescot

England

L34 1PJ

Study participating centre

South London and Maudsley NHS Foundation Trust

Bethlem Royal Hospital

Monks Orchard Road

Beckenham

England

BR3 3BX

Study participating centre

Greater Manchester Mental Health NHS Foundation Trust

Prestwich Hospital

Bury New Road

Prestwich
Manchester
England
M25 3BL

Study participating centre

Birmingham and Solihull Mental Health NHS Foundation Trust

Unit 1
50 Summer Hill Road
Birmingham
England
B1 3RB

Study participating centre

Pennine Care NHS Foundation Trust

225 Old Street
Ashton-under-lyne
England
OL6 7SR

Study participating centre

Somerset NHS Foundation Trust

Trust Management
Lydeard House
Musgrove Park Hospital
Taunton
England
TA1 5DA

Study participating centre

Dorset Healthcare University NHS Foundation Trust

Sentinel House
4-6 Nuffield Road
Nuffield Industrial Estate
Poole
England
BH17 0RB

Study participating centre

Cardiff and Vale U H B

St. Davids Hospital

Cowbridge Road East
Cardiff
Wales
CF11 9XB

Study participating centre

South West Yorkshire Partnership NHS Foundation Trust

Trust Headquarters
Fieldhead Hospital
Ouchthorpe Lane
Wakefield
England
WF1 3SP

Study participating centre

Cornwall Partnership NHS Foundation Trust

Carew House
Beacon Technology Park
Dunmere Road
Bodmin
England
PL31 2QN

Sponsor information

Organisation

University of Liverpool

ROR

<https://ror.org/04xs57h96>

Funder(s)

Funder type

Government

Funder Name

National Institute for Health and Care Research

Alternative Name(s)

National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR

Funding Body Type
Government organisation

Funding Body Subtype
National government

Location
United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan
The datasets generated during and/or analysed during the current study are/will be available upon request. Requests should be made to LCTC by email to gothic2@liverpool.ac.uk

At the end of the trial, after the primary results have been published, the individual participant data (IPD) and associated documentation (e.g. protocol, statistical analysis plan, annotated blank CRF) will be prepared in order to be shared with external researchers.

IPD will only be shared with external researchers if the participants have consented to this onward disclosure in accordance with the Common Law Duty of Confidentiality, or if the external researchers obtain approval to waive this Common Law requirement (i.e. Section 251 Approval via the Confidentiality Advisory Group (CAG) / approval from the Public Benefit & Privacy Panel for Health & Social Care (PBPP)) or if the IPD has been fully anonymised prior to sharing.

All requests for access to the IPD will be assessed by the Sponsor and must be agreed by all Data Controller organisations. If a request is approved, it will be processed by LCTC.

IPD sharing plan summary
Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Study website			28/11/2025	No	No